Papers

3

Total Citations

85

H-Index

2

About

Kevin T. McVary is a leading urologist whose research has fundamentally reshaped the treatment landscape for male lower urinary tract symptoms (LUTS) and erectile dysfunction. His primary focus lies in evaluating and advancing minimally invasive surgical therapies (MISTs) for benign prostatic hyperplasia (BPH), where he has been instrumental in bringing procedures like UroLift, Rezūm, and iTind into mainstream clinical practice. McVary’s work is distinguished by its rigorous, evidence-based approach to comparing these novel interventions against traditional options, as highlighted in his highly cited 2017 review on emerging MISTs (76 citations). Beyond BPH, he has made significant contributions to post-prostatectomy care, using large-scale claims data to illuminate critical disparities in penile prosthesis implantation timing and access. This research directly addresses the unmet needs of patients with persistent erectile dysfunction after radical prostatectomy. Through his blend of clinical innovation and health services research, McVary has not only expanded the therapeutic arsenal for urologists but also championed patient-centered outcomes, ensuring that treatment decisions are guided by robust, real-world evidence.

Research Focus

Key Achievements

2
H-Index
3
Papers
85
Total Citations
28
Avg Citations/Paper
🏆 Most Cited Paper
Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms
76 citations · 2017
📈 Most Prolific Year: 2017 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Southern Illinois University School of Medicine, Loyola University Chicago, Loyola University Medical Center

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago